Salvage chemotherapy with paclitaxel, ifosfamide, and nedaplatin (pin regimen)in patients with urothelial cancer who have received prior cisplatin-based therapy

被引：0
|
作者：
不详
机构：
来源：
EUROPEAN UROLOGY SUPPLEMENTS | 2005年 / 4卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：139 / 139
页数：1
相关论文
共 50 条
  • [31] Irinotecan and nedaplatin as salvage therapy for patients with advanced germ cell tumors following intensive treatment with cisplatin-based combination chemotherapies
    Nishikawa, Masatomo
    Miyake, Hideaki
    Fujisawa, Masato
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2016, 21 (01) : 162 - 167
  • [32] Gemcitabine-Paclitaxel Chemotherapy for Patients with Advanced Urothelial Cancer Refractory to Cisplatin-Based Chemotherapy: Predictive Role of PGK1 for Treatment Response to Cytotoxic Chemotherapy
    Koguchi, Dai
    Matsumoto, Kazumasa
    Ikeda, Masaomi
    Shimizu, Yuriko
    Nakamura, Marie
    Shiono, Yutaka
    Katsumata, Hiroki
    Sato, Yuichi
    Iwamura, Masatsugu
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (20)
  • [33] Quality of life in patients with cisplatin-resistant urothelial cancer: Typical ailments and effect of paclitaxel-based salvage therapy
    Niegisch, Guenter
    Retz, Margitta
    Siener, Roswitha
    Albers, Peter
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2016, 34 (06) : 256.e15 - 256.e21
  • [34] Efficacy of weekly paclitaxel as single agent chemotherapeutic regimen for patients with advanced urothelial cancer progressing after cisplatin-based chemotherapy, 15-year single center retrospective study
    Sideris, S.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S516 - S516
  • [35] Combination of gemcitabine and paclitaxel is a favorable option for patients with advanced or metastatic urothelial carcinoma previously treated with cisplatin-based chemotherapy
    Ikeda, M.
    Matsumoto, K.
    Tabata, K.
    Minamida, S.
    Fujita, T.
    Satoh, T.
    Iwamura, M.
    Baba, S.
    EUROPEAN UROLOGY SUPPLEMENTS, 2012, 11 (01) : E864 - U820
  • [36] Combination of Gemcitabine and Paclitaxel is a Favorable Option for Patients with Advanced or Metastatic Urothelial Carcinoma Previously Treated with Cisplatin-based Chemotherapy
    Ikeda, Masaomi
    Matsumoto, Kazumasa
    Tabata, Ken-ichi
    Minamida, Satoru
    Fujita, Tetsuo
    Satoh, Takefumi
    Iwamura, Masatsugu
    Baba, Shiro
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2011, 41 (10) : 1214 - 1220
  • [37] Gemcitabine plus vinorelbine chemotherapy in patients with advanced bladder carcinoma who are medically unsuitable for or who have failed cisplatin-based chemotherapy
    Türkölmez, K
    Bedük, Y
    Baltaci, S
    Gögüs, Ç
    Gögüs, O
    EUROPEAN UROLOGY, 2003, 44 (06) : 682 - 686
  • [38] Nedaplatin- versus cisplatin-based chemotherapy in the survival time of patients with non-small cell lung cancer
    Shan, Jinlu
    Xiong, Yanli
    Wang, Dong
    Xu, Mingfang
    Yang, Yi
    Gong, Kan
    Yang, Zhenzhou
    Wang, Ge
    Yang, Xueqin
    MOLECULAR AND CLINICAL ONCOLOGY, 2015, 3 (03) : 543 - 549
  • [39] Predictive factors of response to cisplatin-based chemotherapy and the relation of response to survival in patients with metastatic urothelial cancer
    Lisa Sengeløv
    Claus Kamby
    Poul Geertsen
    Lisbeth Juhler Andersen
    Hans von der Maase
    Cancer Chemotherapy and Pharmacology, 2000, 46 : 357 - 364
  • [40] Factors that Predict Neutropenia in Korean Patients with Advanced Urothelial Cancer after Cisplatin-Based Systemic Chemotherapy
    Kwon, Whi-An
    Oh, Tae Hoon
    Lee, Jea Whan
    Seo, Ill Young
    Park, Seung Chol
    UROLOGY JOURNAL, 2018, 15 (04) : 168 - 172
12345